Tumores Urológicos
Estudo de braço único | Ablação focal estendida do câncer de próstata localizado com eletroporação irreversível de alta frequência.
12 Jul, 2022 | 11:21hExtended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial – JAMA Surgery (link para o resumo – $ para o texto completo)
Comentário: Novel Focal Therapy Yields Low Rate of Serious Prostate Cancers — Trial’s 6-month rate of 6% was superior to historical control – MedPage Today (necessário cadastro gratuito)
Conteúdo relacionado: Small study shows feasibility of MRI-guided focused ultrasound ablation for localized intermediate-risk prostate cancer
Comentário no Twitter
This single-arm objective performance criteria trial indicated excellent efficacy and safety profile of the second-generation high-frequency irreversible electroporation as primary treatment for localized prostate cancer. https://t.co/FheqcxJeA5
— JAMA Surgery (@JAMASurgery) July 7, 2022
Estudo randomizado | Orteronel para câncer de próstata metastático sensível a hormônio.
11 Jul, 2022 | 13:28hComentário: Orteronel Misses Goal in Metastatic Hormone-Sensitive Prostate Cancer – HealthDay
Comentário no Twitter
⛔ SWOG-1216: Orteronel did not improve overall survival for metastatic hormone sensitive #ProstateCancer ➡️ https://t.co/aejFNEb7bM #JCO #PCSM @theNCI @SWOG @neerajaiims @shilpaonc pic.twitter.com/LP5oHQqSIg
— Journal of Clinical Oncology (@JCO_ASCO) May 6, 2022
Diretriz de consenso | Função da PET/TC de antígeno de membrana prostática em pacientes com câncer de próstata em relação à terapia com radioligante [177Lu] Lu-PSMA.
7 Jul, 2022 | 12:15hM-A de rede | Radioterapia em alta dose ou terapia de deprivação androgênica como intensificadores do tratamento para câncer de próstata localizado.
7 Jul, 2022 | 11:46hHigh-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium – European Urology (link para o resumo – $ para o texto completo)
Comentário no Twitter
New In Press: High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortiumhttps://t.co/rZnBjvccNe@AmarUKishan @DrSpratticus et al. pic.twitter.com/uCrg7sRmsS
— European Urology (@EUplatinum) April 25, 2022
Estudo randomizado | Efeito do levofloxacino sobre a eficácia e os eventos adversos no tratamento intravesical com BCG para câncer de bexiga.
5 Jul, 2022 | 11:34hDefinição de consenso e recomendações de tratamento: câncer de bexiga sem invasão muscular de risco intermediário.
22 Jun, 2022 | 21:24hIntermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group – European Urology – Oncology (se o acesso a este link for pago, tente este)
Comentário do autor no Twitter
Intermediate-risk NMIBC: Updated Consensus Definition & Management Recs from IBCG (International Bladder Cancer Group)
Full text: https://t.co/QaqGqRN3AE @drtanws @garysteinbergmd @DrShariat @UrogerliMD @MRoupret @spsutkaMD @joanfundi @MarekBabjuk @SWilliams_MD #bladdercancer pic.twitter.com/XQ1sdhqXPZ— Ashish M. Kamat, MD, MBBS (@UroDocAsh) June 17, 2022
Estudo randomizado | Vigilância ativa com enzalutamida em monoterapia vs. vigilância ativa isolada em pacientes com risco baixo ou intermediário de câncer de próstata localizado.
22 Jun, 2022 | 20:57hComentário convidado: To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence – JAMA Oncology (gratuito por tempo limitado)
Vídeo criticando o artigo: ENACT trial | A Study That Makes Pharma Rich and Patients’ Poor | I break it down – by Vinay Prasad
Comentários no Twitter
55% fatigue and 36% gynecomastia. In AS patients.
Why do we keep trying to escalate when the data CLEARLY say we should continue to de-escalate? https://t.co/LY1kD0jN65
— Chris Barbieri (@Chris_Barbieri1) June 17, 2022
The phase 2, open-label ENACT trial compares the efficacy & safety of enzalutamide monotherapy vs active surveillance in patients with low- or intermediate-risk localized #prostatecancer. https://t.co/q9FrL14em1 #PCSM #GUCSM
— JAMA Oncology (@JAMAOnc) June 16, 2022
Estudo de braço único fase 2B | Terapia focal centrada em ultrassom e guiada por ressonância magnética para pacientes com câncer de próstata de risco intermediário.
21 Jun, 2022 | 12:35hMRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comunicado de imprensa: High-intensity focused ultrasound (HIFU) can control prostate cancer with fewer side effects – Memorial Sloan Kettering Cancer Center
Comentário no Twitter
In single-arm phase IIb trial of MRI-guided focused ultrasound therapy in 101 men with primary, group 2‒3 intermediate-risk untreated prostate adenocarcinomas, 88% had no evidence of group ≥2 prostate cancer in the treated area at 2 years: https://t.co/xLpqfFm8Ds #PCSM
— NatureRevClinOncol (@NatRevClinOncol) June 16, 2022
Resultados de longo prazo de estudo randomizado | Radioterapia prostática para homens com câncer de próstata metastático.
16 Jun, 2022 | 13:37hNovo estudo associa a ingestão de laticínios com maior risco de câncer de próstata.
16 Jun, 2022 | 13:29hComunicado de imprensa: New study associates intake of dairy milk with greater risk of prostate cancer – Loma Linda University Adventist Health Sciences Center
Estudo original: Dairy foods, calcium intakes, and risk of incident prostate cancer in Adventist Health Study–2 – American Journal of Clinical Nutrition (link para o resumo – $ para o texto completo)